DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l3pttx/moderate_to) has announced the addition of the "Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanism in the Management of Pain " report to their offering.
Globally, pain is one of the important therapy areas with a market size of over $50b in 2013, and is expected to grow at 10%. The recent patent expiry of Cymbalta and Lyrica (2018) will have significant impact on the overall pain market size in the near future. However, several pipeline molecules are emerging to fill this gap. The importance of abuse deterrent labeling in the formulations can be better understood from FDA's non-approval of oxycontin generics in 2013. The revised labeling with abuse deterrence has protected Purdue's oxycontin revenue slide from its generization.
In the wake of abusive potential of opioids drugs reported all across the US, FDA recently drafted guidance for evaluation and labeling of opioids formulations based on their ability to reduce its abusive potential (tier 1 to 4). Despite the process being in nascent stage, several specialty companies have already ventured into the development of abuse deterrent formulations to reap benefits in the near future.
In this report, we have discussed a number of novel delivery technologies employed in the formulation of abuse deterrent product, technologies employed in enhancing patient compliances and emerging novel mechanisms in the management of pain. Renewed interest on pain therapy is vision as recently Biogen Idec acquired Convergence's CNV1014802 (Nav 1.7 sodium channel blocker) to expand its neuropathic pain portfolio and we believe several such acquisitions will happen in the near term.
Key Topics Covered:
1. Management of Pain
2. FDA Schedule for Controlled Substances and Advantage of Schedule III Over II
3. FDA Guidelines for the Development of Abuse Deterrent Formulations
4. Abuse Deterrent Technology Platforms Employed in Marketed Drugs and Pipeline
5. Pipeline Analysis of Novel Mechanism in Pain Therapy
6. Late Stage Pipeline Developments in Neuropathic Pain
7. FDA Perspective on Abuse Deterrent Formulations (Opioids) Companies mentioned:
For more information visit http://www.researchandmarkets.com/research/l3pttx/moderate_to
